Corren et al. [101], in a phase 2, randomized, double-blinded, placebo-controlled, dose-ranging trial of the anti-TSLP antibody tezepelumab, reported a similar rate of clinically significant exacerbations in adult patients with moderate-to-severe uncontrolled asthma that received tezepelumab compared to those who received a placebo. This evidence concerns the gene TSLP and asthma.